Paul Edick

Paul Edick

Chief Executive Officer chez XERIS BIOPHARMA HOLDINGS, INC.

Fortune : 8 M $ au 31/03/2024

67 ans
Health Technology
Retail Trade
Consumer Non-Durables

Profil

Paul R.
Edick
founded GANIC Pharmaceuticals, Inc. in 2008, where he worked as Chief Executive Officer in 2010.
Mr. Edick also currently works at Xeris Biopharma Holdings, Inc., as Chairman & Chief Executive Officer from 2021.
Mr. Edick also formerly worked at Xeris Pharmaceuticals, Inc., as Chairman, President & Chief Executive Officer from 2017 to 2020, MedPointe, Inc., as President & Chief Executive Officer from 2002 to 2008, MedPointe Healthcare, Inc., as Chief Executive Officer from 2006 to 2008, Durata Therapeutics, Inc., as President, Chief Executive Officer & Director from 2012 to 2014, Veloxis Pharmaceuticals A, as Chairman from 2009 to 2011, Milestone Pharmaceuticals, Inc., as Chairman, Life Cycle Pharma A, as Chairman in 2011, Iterum Therapeutics Plc, as Chairman from 2015 to 2019, NewLink Genetics Corp., as Independent Director from 2011 to 2018, Informed Medical Communications, Inc., as Director from 2006 to 2011, Circassia Ltd., as Non-Executive Director in 2013, Neos Therapeutics, Inc., as Independent Director from 2015 to 2018, Sucampo Pharmaceuticals LLC, as Independent Director, PDL BioPharma, Inc., as Independent Director from 2015 to 2018, Amerita, Inc., as Director, Niox Group Plc, as Independent Non-Executive Director from 2013 to 2016, Baxter Healthcare Corp., as Principal from 1978 to 1990, Procter & Gamble Co., as Sales Representative from 1977 to 1978, Vicuron Pharmaceuticals LLC, as President, G.D.
Searle & Co., Inc., as President-Asia Pacific, Canada & Latin America in 2002, Pharmacia Corp., as VP, President-Asia Pacific & Latin America, MedPointe Capital Partners LLC, as President, 3G Advisors LLC, as Founding Partner, and Searle Pharmaceuticals Pvt Ltd., as President-Asia Pacific, Canada & Latin America.
Mr. Edick received his undergraduate degree from Hamilton College (New York).

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
31/01/2024 3 821 494 ( 2,72% ) 8 M $ 31/03/2024

Postes actifs de Paul Edick

SociétésPosteDébut
XERIS BIOPHARMA HOLDINGS, INC. Chief Executive Officer 05/10/2021
Tous les postes actifs de Paul Edick

Anciens postes connus de Paul Edick

SociétésPosteFin
ITERUM THERAPEUTICS PLC Chairman 13/06/2019
PDL BIOPHARMA, INC. Director/Board Member 31/12/2018
LUMOS PHARMA, INC. Director/Board Member 30/04/2018
NEOS THERAPEUTICS, INC. Director/Board Member 27/04/2018
NIOX GROUP PLC Director/Board Member 17/05/2016
Voir l'expérience en détail de Paul Edick

Formation de Paul Edick

Hamilton College (New York) Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Paul Edick

Relations

100 +

Relations au 1er degré

27

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées5
PROCTER & GAMBLE COMPANY

Consumer Non-Durables

MILESTONE PHARMACEUTICALS INC.

Health Technology

NIOX GROUP PLC

Health Services

ITERUM THERAPEUTICS PLC

Health Technology

XERIS BIOPHARMA HOLDINGS, INC.

Health Technology

Entreprise privées21

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Process Industries

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Retail Trade

Health Technology

Retail Trade

Life Cycle Pharma A/S

3G Advisors LLC

Health Technology

Health Technology

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Paul Edick